Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Operating Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Operating Margin for 16 consecutive years, with 161.48% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 14612.0% to 161.48% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 13.82% through Dec 2025, down 1122.0% year-over-year, with the annual reading at 13.82% for FY2025, 1122.0% down from the prior year.
  • Operating Margin for Q4 2025 was 161.48% at Harvard Bioscience, up from 0.96% in the prior quarter.
  • The five-year high for Operating Margin was 161.48% in Q4 2025, with the low at 228.11% in Q1 2025.
  • Average Operating Margin over 5 years is 3.82%, with a median of 0.58% recorded in 2021.
  • Peak annual rise in Operating Margin hit 14612bps in 2025, while the deepest fall reached -21881bps in 2025.
  • Over 5 years, Operating Margin stood at 5.14% in 2021, then surged by 211bps to 16.0% in 2022, then plummeted by -94bps to 1.0% in 2023, then skyrocketed by 1434bps to 15.36% in 2024, then skyrocketed by 951bps to 161.48% in 2025.
  • According to Business Quant data, Operating Margin over the past three periods came in at 161.48%, 0.96%, and 4.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.